
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure is showing a strong fundamental setup because 2Q26 revenue rose 16% year over year to $183.6 million, with growth across all three commercial products, gross margin expanding to 78%, and total active patients reaching 5,128 globally. The company’s outlook is supported by accelerating adoption in the core GBM franchise, an encouraging Optune Pax launch with 418 prescriptions and 285 active patients in 2Q26, and especially the rapid uptake of Optune Lua in Japan, where active patients rose from 6 in 1Q26 to 64 and revenue reached $1.8 million. Management also improved 2026 revenue guidance to $710 million to $725 million and adjusted EBITDA guidance to $0 million to $15 million while cutting R&D spending by about $90 million, signaling that commercial momentum is improving even as the pipeline advances toward additional regulatory and clinical catalysts.
Bears say
NovoCure is facing a negative outlook because the FDA’s Not Approvable Letter for Optune Mya in NSCLC brain metastases signals meaningful regulatory risk and weakens confidence in the company’s ability to expand its TTFields franchise. The cited uncertain clinical benefit, along with management’s need to determine whether approval is possible without additional studies, increases execution risk and undermines visibility into future commercialization. Beyond this setback, the thesis still depends on Pax and Lua proving they can drive durable growth beyond Gio, while the limited commercial opportunity in brain metastases and uncertainty around treatment duration constrain upside.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Novocure (NVCR) Forecast
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares